<DOC>
	<DOCNO>NCT01602224</DOCNO>
	<brief_summary>The purpose study evaluate investigational drug call tabalumab participant Multiple Myeloma ( MM ) try least one therapy past . Tabalumab give combination standard dose two drug often use treat MM . Study doctor collect information effectiveness side effect therapy .</brief_summary>
	<brief_title>A Study Tabalumab Participants With Previously Treated Multiple Myeloma ( MM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have symptomatic and/or progressive MM previously treat least 1 3 prior line therapy Have measurable disease Have give write informed consent prior studyspecific procedure Have adequate organ function Treatment prior autologous transplant permit Are enrolled discontinue clinical trial drug device within 21 day prior first dose assigned study treatment Have le minimal response progressive disease within 60 day recent therapy proteasome inhibitor Plan proceed autologous transplant consolidation participation trial Have active infection ongoing treatment systemic infection ( `` ongoing treatment '' include prophylactic antiinfectives ) , , chest xray suggestive tuberculosis , history/risk chronic/latent infection may reactivate presence study therapy Have follow : positive test result human immunodeficiency virus ( HIV ) positive test hepatitis B , define positive hepatitis B surface antigen ( HBsAg+ ) , OR positive antihepatitis B core antibody AND positive hepatitis B deoxyribonucleic acid ( HBV DNA ) , OR positive antihepatitis B surface antibody ( HBsAb+ ) AND positive hepatitis B deoxyribonucleic acid ( HBV DNA ) positive test result hepatitis C virus ( HCV ) , define positive hepatitis C antibody ( HepCAb ) AND confirm positive via hepatitis C recombinant immunoblot assay Have significant allergy human/humanized monoclonal antibody , opinion investigator , pose unacceptable risk participant Have know hypersensitivity contraindication study therapy excipients Prior allogeneic hematopoietic stem cell transplant Prior therapy experimental agent target Bcell activate factor ( BAFF ) , include LY2127399 Have correct QT ( QTc ) interval &gt; 500 millisecond ( msec ) baseline 12lead electrocardiogram ( ECG ) Have Waldenstrom 's macroglobulinemia History malignancy adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , situ prostate cancer , eligible regardless time diagnosis/treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>